86 related articles for article (PubMed ID: 8977931)
1. Evolution of tumor necrosis factor-alpha serum concentrations in HIV infected individuals treated with zidovudine.
Morlat P; Chene G; Ragnaud JM; Mercie P; Grobost F; Bernard N; Lacoste D; Beylot J; Aubertin J
Pathol Biol (Paris); 1996 Oct; 44(8):716-9. PubMed ID: 8977931
[TBL] [Abstract][Full Text] [Related]
2. Elevated levels of circulating intercellular adhesion molecule 1 and tumor necrosis factor alpha in the serum of children vertically infected with HIV-1.
Obregón E; Börner C; Navarro J; Gurbindo MD; Fernández-Cruz E; Muñoz-Fernández MA
Pediatr AIDS HIV Infect; 1996 Dec; 7(6):413-7. PubMed ID: 11361498
[TBL] [Abstract][Full Text] [Related]
3. [Tumor necrosis factor-alpha in human immunodeficiency virus infection].
Llobet P; Muga R; González JA; Abad E; Tor J; Rey-Joly C
Med Clin (Barc); 1995 Mar; 104(10):369-72. PubMed ID: 7707730
[TBL] [Abstract][Full Text] [Related]
4. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
[TBL] [Abstract][Full Text] [Related]
5. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
[TBL] [Abstract][Full Text] [Related]
6. Cytokine expression during syphilis infection in HIV-1-infected individuals.
Knudsen A; Benfield T; Kofoed K
Sex Transm Dis; 2009 May; 36(5):300-4. PubMed ID: 19265730
[TBL] [Abstract][Full Text] [Related]
7. [Zidovudine plus didanosine in HIV infected asymptomatic patients previously treated with zidovudine].
López-Martínez C; Guarner J; Magis-Rodríguez C; Uribe-Zúñiga P; del Río-Chiriboga C
Rev Invest Clin; 1998; 50(4):335-9. PubMed ID: 9830323
[TBL] [Abstract][Full Text] [Related]
8. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
9. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
[TBL] [Abstract][Full Text] [Related]
10. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
[TBL] [Abstract][Full Text] [Related]
14. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
15. Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine.
van Leeuwen R; Lange JM; Nijhuis M; Schuurman R; Reiss P; Danner SA; Boucher CA
Antivir Ther; 1997 Apr; 2(2):79-90. PubMed ID: 11322279
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.
Yerly S; Denereaz N; Mermillod B; Hirschel B; Perrin L
Antivir Ther; 1996 Aug; 1(3):167-71. PubMed ID: 11322250
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
18. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
Justice AC; Stein DS; Fusco GP; Sherrill BH; Fusco JS; Danehower SC; Becker SL; Hansen NI; Graham NM;
J Clin Epidemiol; 2004 Jan; 57(1):89-97. PubMed ID: 15019015
[TBL] [Abstract][Full Text] [Related]
19. Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection.
Anderson AM; Kosinski AS; Bartlett JA
Antivir Ther; 2007; 12(7):1041-8. PubMed ID: 18018762
[TBL] [Abstract][Full Text] [Related]
20. Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy.
García F; Vidal C; Plana M; Cruceta A; Gallart MT; Pumarola T; Miro JM; Gatell JM
Clin Infect Dis; 2000 Feb; 30(2):392-4. PubMed ID: 10671348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
